Closely held JVP Labs is developing the only non-invasive, real-time cardiac filling pressure monitoring solution for managing congestive heart failure (CHF) patients—for both in the hospital and at home.
“CHF is one of the most complex conditions to manage due to a lack of real-time, actionable physiological data. Our device can isolate and measure the jugular venous pressure (JVP) height in CHF patients. Using an ECG-gated optical imaging device, we isolate the JVP height through advanced computer vision algorithms,” Mr. Paul Weber, CEO of JVP Labs, says in an interview with BioTuesdays.
Mr. Weber explains that cardiac filling pressure is the earliest indicator of changes in a CHF patient’s condition, assessable through JVP—the pressure in a major vein in the neck that reflects how well the right side of the heart is functioning. Elevated JVP can signal heart problems or fluid overload, making it a key clinical sign doctors observe. “Think of the veins like drain pipes, and the heart is the pump that pulls water (blood) through the pipes. If the pump is weak, water backs up, and pressure builds up in the pipes — that’s what’s happening when JVP is high.”
In the U.S. alone, CHF affects 6.9 million people and burdens the healthcare system by more than $30 billion annually. Of these cases, 25% are readmitted within 30 days of initial hospitalization. CHF is the leading cause of hospitalization among individuals aged 65 and older, and is one of the leading costs to Medicare in the U.S.
“JVP is clinically accepted and recommended in practice guidelines, but the current method is manual and difficult to master for non-cardiologists to perform accurately. As a result, it’s underused, and CHF is plagued by a lack of tools that provide early insight into changing conditions,” Mr. Weber notes.
He points out that the current standard of care involves administering diuretics and monitoring weight changes and/or fluids in/fluids out—a process that can take up to 72 hours and contributes to average hospital stays of three to 14 days. Many patients are discharged with unresolved congestion, leading to frequent readmissions. “The issue is that many discharging physicians don’t have the expertise or tools they need to identify and quantify the level of congestion.”
“Invasive pressure monitoring has proven highly effective for early detection of cardiac filling pressures—often before the patient experiences symptoms—but it is very costly and so it is not widely adopted,” Mr. Weber adds.
The invasive cardiac filling pressure monitoring method involves an implantable device inserted into the pulmonary artery, via a catheter. The cost of the invasive process is approximately $30,000 per unit, with an additional $5,000 in annual management costs.
“Our JVP technology also measures cardiac filling pressures—but in a real time, non-invasive framework and at a very low cost—in the hundreds of dollars as compared to tens of thousands with the conventional invasive version,” Mr. Weber asserts. “This empowers general physicians and healthcare practitioners to detect congestion at a very early stage, enabling them to intervene and avoid the pitfalls of early discharge.”
Mr. Weber emphasizes the portability and ease-of-use of the device. “The disruptive nature of our non-invasive solution is its ease-of-use and ability to seamlessly integrate into existing clinical workflows. Leveraging computer vision, it enables healthcare providers—from specialists to nursing staff—to easily capture key images and measurements during rounds and download them on-site as needed.”
“There’s also a major opportunity around predictive modeling and AI for cardiovascular diseases, since we’re collecting novel data that’s never been available before,” he adds.
Joining Mr. Paul Weber in the BioTuesdays interview, is Mr. Michael Weber, CRO of JVP Labs, who outlines the company’s three primary focus areas: 1) monitoring inpatient progress while on therapeutics; 2) ensuring reduced congestion at discharge; and 3) in home monitoring to keep patients stable in a low-cost care setting.
“Currently, we’re focused on our first phase: in-hospital monitoring. But we’re developing a second phase—the home-based monitoring—which promises to save healthcare systems significant costs,” he says. “Our forthcoming device, JVPHome, enables patient care from home, reducing the need for lengthy and costly hospital stays and readmissions. With the push of a single button, non-invasive remote monitoring will be possible in less than a minute. This greatly improves patient outcomes and quality of life, while significantly lowering health system costs.”
With CHF recognized globally as a major clinical challenge, Mr. Michael Weber says JVP Labs is receiving strong support from leading key opinion leaders (KOLs) such as world-renown cardiologist, Dr. Heather Ross, CM, MD, DSc, MHSc, FRCP (C), FACC. The company is actively collaborating with Mayo Clinic, University Health Network (UHN), and Newfoundland Health Services, with additional interest from top tier medical institutions. “UHN and Mayo Clinic are spearheading our data collection for the FDA submission,” he adds.
From an IP perspective, Mr. Paul Weber says the company is in a strong position having secured two U.S. patents covering broad claims in its core technology, and moving through national phase in multiple target jurisdictions.
“Regulatory-wise, we’re preparing for a 130-patient FDA trial later this year, in collaboration with UHN and Mayo Clinic. We anticipate a Class II De Novo designation in late-2026,” he adds.
Mr. Weber outlines that the company is currently in its seed funding stage, having raised just under $4 million in non-dilutive funding and $1.5 million through a convertible note. “This year, we’re in the process of raising $7.5 million. These funds will primarily be used to advance our first-generation in-hospital device through FDA trials, secure clearance, and prepare for market launch. This will enable us to engage leading KOLs and strategic partners, as well as initiate development of our in-home device. With additional funding from a Series A round expected in mid-to-late 2026, we plan to complete development of the in-home device, obtain FDA clearance, and move toward commercialization.”
Regarding the commercialization strategy, Mr. Weber explains, “Our in-hospital product is currently being used to generate clinical evidence and establish strategic relationships. Our plan is to develop a second-generation version that will be ready to scale across hospitals and skilled nursing facilities by 2027—followed by the launch of our in-home remote monitoring system.”
In closing, Mr. Weber emphasizes, “CHF is a massive, unresolved global clinical challenge and we believe our solution has the potential to transform patient care. Our experienced leadership team is energized by the strong support from key strategics and KOLs and very encouraged by the early traction we’re gaining in the industry.”
Editor’s Note: This article does not constitute an offer to sell or the solicitation of an offer to buy any securities of JVP Labs, and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
• • • • •
To connect with JVP Labs or any other companies featured on BioTuesdays, send us an email at editor@biotuesdays.com.
